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Introduction
Agmatine was first discovered in 1910 and was long thought 
to be a component of bacteria, plants and select invertebrates 
[1, 2]. However, the discovery of agmatine being expressed 
in rat brains in the 20th century indicated that mammalian 
agmatine is synthesized and not a result of diet or bacteria 
growth [1]. Agmatine is the primary endogenous peptide 
that is synthesized via the decarboxylation of L-arginine, 
which originates from arginine decarboxylase (ADC), then 
hydrolyzed by agmatinase [2-4]. It can be found abundantly 
in the stomach, small intestines, aorta and throughout the 
brain and spinal cord, although in significantly less concen-
tration [5]. As depicted in Fig. 1, the role and concentration 
of agmatine in the central nervous system (CNS) is region 
specific. The highest concentration of agmatine is found in 
the gastrointestinal tract; this is mainly due to dietary inges-
tions and local synthesis of gut microflora [6-8]. In the gas-
trointestinal tract, agmatine is believed to work as an inverse 
agonist on receptors which results in hypertension and exac-
erbated gastric mucosal injury [8, 9]. Agmatine plays a role in 
maintaining homeostasis in the brain, heart and surround-
ing vascular structure by modulating calcium levels [5, 10-
13]. Agmatine affects many cellular mechanisms in the CNS 
such as cellular apoptosis, regulation of inflammation, and 
neural edema. It has been shown to inhibit the formation of 
advance glycation-product, which is known to damage the 
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extracellular protein, leading to many neurodegenerative 
diseases [14]. Agmatine has been shown to have a regulatory 
effect on the fate of, proliferation and differentiation of neu-
ral progenitor cells in the adult hippocampus, by modulating 
regulatory functions of neurogenesis such as nitric oxide 
synthase (NOS) stress and glutamate levels [9, 13]. The main 
roles of agmatine in the mammalian body are thought to 
modulate functions associated with cell membrane and cy-
toplasmic targets including neurotransmitters, N-methyl-D-
aspartate (NMDA) receptors, ion channels, and nitric oxide 
(NO), either directly or indirectly (Fig. 1) [1-4, 15, 16]. 
Agmatine: Overview and Biological 
Significance in the Central Nervous System
The literature regarding agmatine has drastically in-
creased over the last decade with a wide range of neurologi-
cal focuses such as ischemic stroke, epilepsy, and psychologi-
cal disorders such as stress, depression, and addiction [2, 9, 
17-19]. Recent studies have shown that agmatine protects 
neurons against glutamate toxicity by inhibiting the produc-
tion of NO in microglia; this mechanism is controlled by 
NMDA receptors [20-24]. It has also been proposed that the 
agmatine related blockades of NMDA receptors may have an 
underlying antidepressant and anti-anxiety effect, which will 
be discussed later [9, 16, 23, 25]. Agmatine has been shown to 
protect neural tissue from ischemic insult by inhibiting NO 
signaling because of its structural similarities to L-arginine, 
making it a competitive NOS inhibitor [26]. Agmatine affects 
many cellular mechanisms in the CNS and has a unique role 
throughout the body. Targeting agmatine and its metabolites 
is a platform that future researcher can work from to gather 
a better understanding of the exact cellular mechanisms and 
their related effects, which will be further discussed. 
Since the discovery of agmatine in the mammalian brain, 
it has been confirmed that agmatine is produced in the 
cortex and brain stem of the brain and also in the spinal 
cord, then stored and synthesized in astrocytes [1, 3, 17]. L-





















Fig. 1. Schematic diagram of the roles of 
agmatine in the brain stem/spinal cord, 
hippocampus, temporal lobe, prefrontal 
and parietal lobe. ERK, Extracellular­
signal­regulated kinases; NO, nitric 
oxide; NOS, nitric oxide synthase; ROS, 
reactive oxygen species; SOD, superoxide 
dismutase; TLX, tailless homolog. This 











































































Fig. 2. Schematic illustration of the synthesis of L­arginine dependent, 
agmatine in the mitochondria of astrocytes. Agmatine is synthesized 
as a result of arginine decarboxylase dependent L­arginine. Arginase 
converts L­arginine to ornithine, which enters the urea cycle and NOS 
initiates the conversion of L­arginine to NO and citrulline. Agmatine 
can be metabolized to putrescine—which can produce spermine and 
spermidine—through agmatinase or be oxidised by diamine oxidase 
to produce guanidinobutyric acid. NO, nitric oxide.
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the prominent glial cell in the brain, also expressing enzyme 
systems that metabolize arginine [15, 27]. L-arginine enters 
the pre-synaptic ending where it is decarboxylated via mito-
chondrial ADC to produce agmatine [1, 17]. The agmatine 
product is then stored in the synaptic vesicles of astrocytes, 
ready to be released by the depolarization of N-type Ca2+ ion 
channels, which remain inactivate due to the reabsorption 
and degradation by agmatinase [17]. 
Agmatine and its metabolites have an influential effect on 
many cellular mechanisms throughout the body, including 
how they are synthesized. As illustrated in Fig. 2, the process 
of synthesizing agmatine through ADC is L-arginine depen-
dent, the substrate for arginase and NOS (Fig. 2) [27]. Argi-
nase hydrolyses L-arginine to ornithine, which enters the 
urea cycle, where NOS initiates the conversion of L-arginine 
to NO and L-citrulline [3, 4]. Agmatine can be metabolized 
to putrescine, through agmatinase [28]. Ornithine and ag-
matine are hydrolyzed by agmatinase to create putrescine, 
a precursor of spermine and spermidine [17]. Spermidine is 
essential for the biosynthesis of pro-insulin, while spermine 
may exert a stimulatory effect on long-term insulin release 
and RNA transcription [28]. Another significant metabolic 
pathway of agmatine, prevalent in the periphery cycle, is 
that agmatine can be metabolized into guanidinobutyric 
acid by the enzyme diamine oxidase, which is then oxidized 
to γ-guanidinobutyrate (Fig. 2) [3, 4, 17, 28]. There is evi-
dence to suggest that agmatine can be characterized as an 
inhibitory subunit for monoamide oxidase, an important 
neurotransmitter regulator, when administered in high con-
centrations (167M) [29]. NOS has been shown to be competi-
tively inhibited by agmatine in vitro, which has a substantial 
impact on the function and actions of agmatine in the mam-
malian brain [17, 30-32]. 
Both endogenous and exogenous agmatine can exert their 
functions on NO and reduce ischemic brain injury in neona-
tal rats, levels of both are also increased during ischemic in-
sults [33, 34]. Kim et al. [32] demonstrated the neuroprotec-
tive functions of agmatine, both in vivo and in vitro through 
reducing the production of NO by competitively inhibiting 
neuronal NOS (nNOS) and isoform NOS (iNOS). ADC is 
localized in astrocytes, so endogenous agmatine produc-
tion is thought to be predominantly in astrocytes which are 
mainly absent in in vivo studies involving cultured neurons. 
This is hypothesized to be the main reason that there is such 
a discrepancy in the neuroprotective effects of agmatine in, 
in vivo and in vitro studies [32]. Moreover, it has also been 
demonstrated that exogenous agmatine can inhibit the ex-
pression of metalloproteinase-2 (MMP-2) and metallopro-
teinase-9 (MMP-9), a protein that plays a pivotal role in the 
integrity of the blood-brain barrier which is essential for ce-
rebral homeostasis [3, 26, 32, 35]. Jung et al. [36] investigated 
endogenous agmatine on inhibiting the expression of MMP-
2 and MMP-9 by induction of endothelial NOS (eNOS) in vitro. 
The findings suggested that endogenous agmatine is able to 
reduce the expression of MMP-2 and MMP-9 by regulation 
of eNOS, NO and the activation of transcription factor 3 [35, 
36]. Excess agmatine that is produced endogenously, protects 
neural progenitor cells from hydrogen peroxide injury; how-
ever, the exact mechanisms of this process are not yet con-
firmed [34, 37, 38]. Agmatine has a diverse and influential 
role throughout the CNS, with many of its capabilities still 
not fully understood. Exogenous and endogenous agmatine 
also have a great influence on the proliferation or differen-
tiation ability of neural progenitor cells in the mammalian 
brain, which we will discuss in more depth in this paper.
Properties of Neural Progenitor Cells
Neurogenesis is known as the functional generation of 
neurons and glial cells from neural progenitor cells in the 
CNS, primarily occurring in the subgranular zone of the 
dentate gyrus [39, 40]. Neural progenitor cells are known as 
the progenitor cells that give rise to almost all of the glial and 
neuronal cell types within the CNS [39, 41]. They are most 
active in the early embryonic and perinatal stages, originally 
thought to be the only active phases [39-42]. However, it 
has since been discovered that neurogenesis continues into 
adulthood in the subgranular zone of the dentate gyrus in 
the hippocampus and in the subventricular zone of the later-
al ventricles [40, 42]. These newly generated neurons migrate 
through the rostral migratory stream to the olfactory bulb 
to differentiate into functional neurons [43]. It is crucial to 
identify a viable source of neural progenitor cells, that is able 
to differentiate into neural like cell, because it is challenging 
to regenerate nervous tissue after insult. The process of iden-
tifying viable sources of neural progenitor cells from various 
sources, to promote neurogenesis post CNS injury. Recent 
studies have also identified human dental pulp stem cells as 
a promising candidate for stem cell therapy as they differen-
tiate in to neuron like cells [44, 45]. These stem cells were de-
rived from ectomesenchyme neural crest, which means they 
have the similar characteristic to that of mesenchymal and 
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neural crest stem cells [45, 46]. Under normal physiological 
conditions, adult neurogenesis in other regions of the CNS is 
extremely limited; however, evidence has emerged that it can 
be induced after neuronal insult [40, 47-49]. The presence 
and degree of neurogenesis in the adult dentate gyrus had 
been linked to crucial cognitive behaviors such as learning, 
memory retention and pattern recognition, both in normal 
and diseased states [47, 48, 50]. 
Neurogenesis of progenitor cells is a complex process that 
involves proliferation, migration, differentiation and func-
tional integration. Post neuronal insult, be that traumatic or 
stroke, the migration of neural progenitor cells increases in 
the tissue lesion [51]. The adaptive mechanism of neuroplas-
ticity is an integral part of the recovery process of brain and 
cognitive function after cerebral injury [52]. Stress-related 
phycological diseases such as bipolar disorder, depression 
and anxiety have been associated with the downregulation of 
neurogenesis in the adult hippocampal region [23, 53]. Adult 
neurogenesis has been linked to having an antidepressant 
effect in mice and also reducing stress levels and improving 
the overall emotional state of the animal [9, 54, 55]. It has 
been observed that in stressed induced mice, agmatine could 
prevent the suppression of neural progenitor cell prolifera-
tion in the subgranular zone [9, 31]. Agmatine can modulate 
long term activity-dependent neuroplasticity in rodents, by 
blocking NMDA receptors and increasing proliferation of 
neural progenitor cells [56]. These discoveries suggest that 
agmatine can induce the proliferation of neural progenitor 
cells, by blocking NMDA receptors, which is important in 
the recovery of CNS diseases. 
The Role of Agmatine on Neural Progenitor 
Cells in the Central Nervous System
Agmatine has also been considered as a neurotransmitter 
due to being heavily localized in the pyramidal cell bodies 
and granule cells of the dentate gyrus and has a modulative 
effect on learning and memory [5, 57, 58]. Recent studies 
have investigated the levels of agmatine in the hippocampus 
of rats throughout the learning and activity phases of the 
performance during the Morris water maze task [28, 59]. In 
one study, the animals that displayed an increase in their 
learning curve also showed an increase in glutamate and 
agmatine levels in the hippocampal region, proposing that 
endogenous agmatine system can be controlled during the 
learning and activity phases [28]. Rushaidhi et al. [59] com-
pleted a study investigating hippocampal agmatine levels in 
rodents throughout phases of cognitive testing. There was 
a significant (78%) increase in agmatine levels in the hip-
pocampal agmatinergic synaptic terminals after the spatial 
learning phase [58]. These results are consistent with other 
studies on the role of agmatine in spatial learning, indicating 
that endogenous agmatine can modulate the learning pro-
cess by working in conjunction with glutamate as putative 
neurotransmitters [28, 58, 59].
The use of neural progenitor cells overexpressing ADC in 
animal models can promote the formation of synapses and 
the recovery of motor function following cerebral ischemia 
[37]. Indicating that this process is a promising candidate 
for cell replacement therapy for ischemic stroke using neural 
progenitor cells, which overexpress ADC that modulates 
excessive calcium levels, prevent mitochondrial membrane 
collapse, and strengthen intracellular calcium resistance [37]. 
The effect that agmatine has on the proliferation of neural 
progenitor cells, is thought to be in relation to the activation 
of extracellular-signal-regulated kinases (ERK) [60]. Cal-
cium, particularly cytosolic and nuclear, is a key regulator 
for many cellular mechanisms such as proliferation, differen-
tiation and apoptosis and even has an influence on cell cycle 
progression [37, 61, 62].
Li et al. [9] have determined that the effect of agmatine on 
progenitor cells depends on both physiological and patholog-
ical conditions. For example, their previous studies displayed 
that agmatine increased the proliferation of hippocampal 
neural progenitors in chronically stressed mice [9]. However, 
this data contradicts Song et al. [60] reports that agma-
tine decreases the proliferation of cultured subventricular 
progenitors yet increased the differentiation to neurons by 
increasing MAP2-positive cells. These contradictory results 
are suggested to be due to the different origin of the cultured 
progenitor cells and different concentrations of agmatine [31]. 
Interleukin-1 Beta (IL-1β) is widely known to be one of the 
most abundant pro-inflammatory cytokines in the mamma-
lian brain; multiple studies suggested that an increase in IL-
1β levels will decrease cellular proliferation and decrease the 
number of post-mitotic neurons [63, 64]. IL-1β expression in 
differentiating and proliferating neural progenitor cells can 
be prevented by interleukin 1 receptor antagonist inhibiting 
the binding of IL-1β to interleukin 1 type 1 receptor [63, 65]. 
Strongly suggesting that agmatine can induce and modulate 
the differentiation and proliferation of neural progenitor 
cells by modulation IL-1β in neuroinflammatory conditions. 
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Several studies have confirmed the importance of lethal-7 
gene (let-7a) and ERK1/2 in the proliferation and self-renewal 
abilities of neural progenitor cells, let-7a having an inhibitory 
effect [66-68]. Song et al. [69] showed that 100 μl of agma-
tine upregulates the differentiation of well-known neuronal 
markers NeuN and doublecortin protein family (DCX) and 
modulates the expression of let-7a, thus increasing neural 
progenitor differentiation [66, 69, 70]. Whereas ERK1/2 has 
an inducive effect on differentiation of neural progenitor 
cells in the subventricular zone, agmatine has been shown 
to regulate this process [64-68, 71, 72]. ERK1/2 and let-7a 
have a close relationship, ERK expression is decreased by 
the overexpression of let-7a, agmatine has been shown to 
promote ERK1/2 expression [64, 71, 72]. Thereby regulating 
let-7a and increasing cell survival and differentiation of neu-
ral progenitor cells [65]. Nuclear receptor, tailless homolog 
(TLX) is known to regulate neurogenesis in the adult hippo-
campus and is essential for regulating the neural progenitor 
cells undifferentiated state [64, 73]. The signaling of ERK is 
promoted by agmatine, and TLX regulates p53 expression 
and explains the correlation between agmatine and TLX on 
the neural progenitor differentiation (Fig. 1) [73]. However, 
as ERK acts on many cellular processes, the exact relation-
ship between ERK and let-7a requires further investigation. 
This data implies that agmatine regulates proliferation and 
differentiation of neural progenitor cells, again proving to 
be a promising therapeutic treatment to increase the dif-
ferentiation of neural progenitor cells in inflammatory CNS 
diseases. 
Therapeutic Application of Agmatine on 
Neuronal Progenitor Cell Therapy in the 
Central Nervous System Disease 
There is an increasing amount of literature and data re-
garding the use of agmatine as a potential therapeutic agent 
for CNS diseases. It has been shown to emulate pre-existing 
mechanisms in the brain, making it a promising candidate 
for therapeutic treatment. As previously mentioned, agma-
tine can be found throughout the mammalian body and 
plays a role in maintaining homeostasis of the brain, heart 
and surrounding vascular structure by modulating calcium 
levels [5, 10, 11, 13]. There is a wide range of neurological 
focuses and applications of agmatine such as Alzheimer’s, 
stroke, epilepsy and psychological disorders such as stress, 
depression and addiction (Table 1) [2, 17-19, 31]. Recent stud-
ies have shown that agmatine protects neurons against gluta-
mate toxicity by inhibiting the production of NO in microg-
lia. This mechanism is controlled by NMDA receptors [8, 31, 
22]. It has been proposed that the agmatine related blockade 
of NMDA receptors may have an underlying antidepressant 
and anti-anxiety effect (Table 1) [13, 16, 23].
Table 1.  Summary of novel approaches and therapeutic treatments for central nervous system diseases, showing neuroprotective effects of agmatine in animal 
models 
Disease Experimental model Target Outcome Reference
Alzheimer’s disease Streptozotocin-induced 
Alzheimer’s 
Neuron apoptosis via NMDA 
receptors and inflammatory 
cytokines (IL-1)
Reduced accumulation of amyloid-beta protein, 
phosphorylation of Tau peptide and 
activation of insulin signal transduction 
[24, 57, 72]
Ischemic stroke Transient middle cerebral artery 
occlusion (2 hours)
Inhibition of neuronal NOS and 
isoform NOS by reducing 
production of NO
Reduced infarct size and decreased production 
of inflammatory cytokines
[26, 33, 34] 
Parkinson’s disease (PD) Intranasal administration of 
MPTP
NMDA receptor & NOS activity Provided a 31% protection of PD [5, 71]
Epilepsy Pentylenetetrazol induces  
seizure (PTZ)
Extracellular glutamate Significantly reduce the severity and decreased 
likelihood of seizure 
[19, 49]
Depression Chronically induced stress 
regimen
Hippocampal neural progenitor 
cells and 5-HT2 receptor
Increased neurogenesis and lessened depressive 
behaviour
[9, 18, 25]
Traumatic brain injury Lateral fluid percussion  
injury (FPI)
Glutamate and NO activity Alleviation of motor and proprioception 
deficits, cerebral infarct size and weight loss
[21, 25]
Spinal cord injury MASCIS (open field locomotor 
scale) 
M1 & M2 Macrophage Reduce locomotive impairments by modulating 
macrophage phenotypes
[26, 70]
Drug addiction Chronic morphine-treated 
model 
Glutamate receptors in the 
hippocampus 
Decreased glutamate release and prevented 
down regulation of NMDA
[32]
IL, interleukin; NO, nitric oxide; NOS, nitric oxide synthases.
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As summarised in Table 1, Feng et al. [33] and Kim et al. 
[26, 32] were also able to show neuroprotective results against 
ischemic brain injury in MCAO models. The suppression 
of NO production by agmatine and the inhibition of nNOS 
expression and activity both showed mechanisms of neuro-
protection against ischemic insult [26, 32]. Targeting M1 and 
M2 macrophage activity, specifically BMP2, which reduces 
M1 macrophage in inflammatory conditions to reduce im-
penitent post spinal cord injury [74]. The inhibition of NOS 
activity and the blocking of NMDA receptors via agmatine 
provided partial protection of MPTP dopaminergic toxicity 
in Parkinson’s disease models [75]. Song et al. [24] targeted 
NMDA receptors, Nrf2 and apoptosis of neurons to reduce 
the accumulation of amyloid-beta (Aβ) plaques and the 
phosphorylation of Tau proteins, thus ameliorating the cog-
nitive decline of streptozotocin-induced Alzheimer’s models. 
Similarly, agmatine reduced Alzheimer’s pathologies in type 
2 diabetes by regulating associated insulin signal molecules 
(Akt and IRS-1), reducing Aβ plaques and improving hippo-
campal neural progenitor cell function [76]. The regulation 
of neural progenitor cells via agmatine, reducing the expres-
sion of IL-1β and thus promoting differentiation in neuroin-
flammatory conditions [64].
The therapeutic potential of agmatine on neural progeni-
tor cells on psychological diseases such as high stress and de-
pression is promising, with a significant amount of literature 
focusing on this relationship. The simulation and increased 
proliferation of neural progenitor cells in the hippocampus 
is known to decrease or reduce depressive-like symptoms 
[23]. With multiple studies displaying results that agmatine 
increases the proliferation of hippocampal progenitor cells, 
this mechanism provides an anti-depressive like effect [9, 18, 
34]. Targeting hippocampal progenitor cells in chronically 
stress-induced mice, agmatine increases neurogenesis, lead-
ing to a decrease in depressive behaviors [9]. 
Unfortunately, many of these applications face various 
technical, ethical and safety obstacles; mainly, heterogene-
ity, neuronal yield, and low survival rate [37]. Further study 
should target how agmatine influences the survival, differ-
entiation, and maturation of the proliferated progenitor cells 
[51, 60]. Utilizing the relationship between agmatine and its 
effect on neural progenitor cells shows very promising neu-
roprotective outcomes in various CNS disease models which 
may one day lead to clinical application. 
Conclusion
The role of the agmatine as potential neuroprotectant for 
the treatment of acute brain disorders and spinal cord injury 
is being strongly recognized, along with a more detailed un-
derstanding of the mechanisms underlying this beneficial ef-
fect. There is also an increasing amount of data surrounding 
the use of neural progenitor cells as a key player for thera-
peutic treatments for various CNS disorders. The significant 
amount of literature showing positive effects of agmatine as 
a neuroprotective agent in in vitro and in vivo models of neu-
rotoxicity and neural inflammation offer a favorable direc-
tion for future research and promising outcomes for thera-
peutic treatment for CNS diseases. Further investigation is 
required to comprehend the full effects of agmatine in neural 
progenitor cell research and to understand the mechanism 
and neuroprotective effect as well as the potential for thera-
peutic application. 
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